Sino Biological Launches 4RISE™ High-Throughput Wet-Lab Services to Accelerate AI-Driven Drug Discovery

Résumé détaillé

HOUSTON, Nov. 13, 2026 /PRNewswire/ -- AI-designed protein binders require wet-lab validation to confirm their target-binding activity. Sino Biological, Inc. (Shenzhen Stock…

HOUSTON, Nov. 13, 2026 /PRNewswire/ -- AI-designed protein binders require wet-lab validation to confirm their target-binding activity. Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, announced its 4RISE™ high-throughput wet-lab validation services for AI-designed protein binders. The services feature 3-hour cell-free expression, AI-ready binding data in as little as 3 days, and real-time API access to structured target-binding data, helping AI-focused life sciences researchers move faster and gain deeper insights.

Sino Biological's XPressMAX™ Cell-Free Protein Synthesis (CFPS) platform enables recombinant protein synthesis in just 3 hours, with expression success rates exceeding 99% in established workflows. Supporting the synthesis of miniproteins, VHHs, scFvs, Fabs, enzymes, and cytokines, the platform accelerates experimental testing of AI-designed protein candidates, enabling faster feedback and design iterations.

Using Carterra high-throughput SPR, Biacore SPR, and Octet BLI, 4RISE™ delivers high-throughput binding screening, kinetic analysis, and affinity determination for candidate protein. Combined with CFPS, the workflow delivers sequence-to-AI-ready binding data in as little as 3 days. Structured binding data are accessible in real time via API, enabling seamless data retrieval for downstream research and analysis.

To support diverse research needs in AI-driven binder discovery, 4RISE™ offers flexible screening and characterization workflows tailored to different candidate formats and validation objectives. Rapid Hit Discovery identifies binding-positive miniproteins and VHHs through crude-supernatant screening. Comparative Binder Screening evaluates purified candidates under standardized conditions to support candidate prioritization.

Beyond binding, 4RISE™ also provides 20+ developability assays, 1,000+ protein bioactivity assays, and 10+ cell-based functional assays, supporting in-depth candidate…

Sino…

Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.